POLR2A (Ser5) (12C8) Monoclonal Antibody

$Lane 1: Hela cells lysates; Lane 2: MCF-7 cells lysates; Probed with POLR2A (Ser5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:500 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Hela cells lysates; Lane 2: MCF-7 cells lysates; Probed with POLR2A (Ser5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:500 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

Flow cytometric analysis of Hela cells with POLR2A (Ser5) (12C8) Monoclonal Antibody (bsm-52962R) at a 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human breast cancer tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast cancer tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse bladder tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse bladder tissue incubated with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$IF(ICC) staining with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:200 in Hela cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:200 in Hela cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100 in MCF-7 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:100 in MCF-7 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:200 in PC-12 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Phospho-POLR2A (S5) (12C8) Monoclonal Antibody (bsm-52962R) at 1:200 in PC-12 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

Applications

WB
FCM
IHC-P
IF(ICC)

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-52962R
Product Name	POLR2A (Ser5) (12C8) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC)
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Synthetic phospho-peptide corresponding to residues surrounding Ser5 of human POLR2A
Modification Site	Ser5
Clonality	Monoclonal
Clone #	12C8
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	5430
Swiss Prot	P24928
Synonyms	DNA-directed RNA polymerase II subunit RPB1, DNA-directed RNA polymerase II subunit A, DNA-directed RNA polymerase III largest subunit, RNA-directed RNA polymerase II subunit RPB2, RNA polymerase II subunit B1, POLR3A
Background	RNA polymerase II (Pol II) is an enzyme that is composed of twelve subunits and is responsible for the transcription of protein-coding genes. Transcription initiation requires Pol II-mediated recruitment of transcription machinery to a target promoter, thereby allowing transcription to begin. The largest subunit of Pol II (referred to as RPB1 or RPB205) is a 1,840 amino acid protein that contains one C2H2-type zinc finger and a C-terminal domain comprised of several heptapeptide repeats. Although Pol II function requires the cooperation of all twelve subunits, the largest subunit conveys Pol II catalytic activity and, together with the second largest subunit, forms the active center of the Pol II enzyme. Additionally, the large subunit participates in forming the DNA-binding domain of Pol II, a groove that is necessary for transcription of the DNA template. Without proper function of the large subunit, mRNA synthesis and subsequent transcription elongation cannot occur.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200